Spn-538
Headache Disorders
Supernus Pharmaceuticals, Inc.Phase 4 / ApprovedDormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Headache Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Idebenone Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 3 | B |
Bimatoprost Manistee Partners | Phase 2 | CCC |
Xeomin® Norwegian University of Science and Technology | Phase 1/2 | CCC |
GLYCERIN,ANHYDROUS Norwegian University of Science and Technology | Phase 1/2 | CC |
Glucagon Norwegian University of Science and Technology | Phase 1/2 | CC |
View all 13 →
Same molecule, other indications
Spn-538 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →